Programme to Improve Life and Longevity Pilot
Is a polypill tolerable and effective at improving blood pressure and cholesterol control in people at raised risk of cardiovascular disease
Health Research Council of New Zealand
400 participants
Oct 2, 2008
Interventional
Conditions
Summary
Cardiovascular disease (CVD) is the leading cause of hospitalisation and premature death in many countries globally. One of the most hotly debated issues in clinical research is whether a “polypill” (a new combination medication containing aspirin and agents to lower blood pressure and cholesterol) can really reduce cardiovascular disease by three-quarters or more. This clinical trial will assess the safety and tolerability of a polypill, and its effects on blood pressure and cholesterol in people at increased risk of CVD.
Eligibility
Inclusion Criteria1
- Adults with 5-year cardiovascular risk of at least 7.5%. 2. No definite indication or contraindication for treatment with low dose aspirin, Angiotensin-Converting Enzyme (ACE) inhibitor, low-dose diuretic or statin. 3. Participant able to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Polypill - one tablet once a day for 12 weeks. Polypill contains aspirin 75mg, simvastatin 20mg, lisinopril 10mg and hydrochlorothiazide 12.5mg.
Locations(6)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000099426